Univest
Univest
  • Markets

4 Largecap Kotak Mutual Fund Stocks to Watch for Future Multibagger Potential: Shriram Finance, Torrent Pharma, BSE and Indian Bank

  • October 29, 2026
  • Posted by: Manan Bisht
  • Category: Best Stocks
No Comments
4 Largecap Kotak Mutual Fund Stocks to Watch for Future Multibagger Potential: Shriram Finance, Torrent Pharma, BSE and Indian Bank

Shriram Finance Rs 826.05. Torrent Pharma Rs 4,557. BSE Rs 3,485. Indian Bank Rs 839.80. Market caps from Rs 1.11 lakh crore to Rs 2.05 lakh crore. Data as of 28 Oct 2026.

Quick Answer

Shriram Finance, Torrent Pharma, BSE and Indian Bank are the 4 picks in this Kotak mutual fund stocks watchlist, with market caps between Rs 1.11 lakh crore and Rs 2.05 lakh crore. Shriram Finance stands out for the largest market cap at Rs 2,04,755 crore, while Torrent Pharma offers 20.34% revenue growth in FY26. PE ratios run from 8.36 to 80.23, so compare each one with its industry PE before investing. All figures are as of 28 October 2026.

Kotak mutual fund stocks to watch for multibagger potential start with a simple filter: size, a clean financial record and earnings that keep growing. Shriram Finance, Torrent Pharma, BSE and Indian Bank meet that test, with market caps from Rs 1.11 lakh crore to Rs 2.05 lakh crore and Shriram Finance offering the largest market cap at Rs 2,04,755 crore. Each of these companies has Kotak Mutual Fund or one of its schemes listed among its top domestic institutional holders, a return on equity of at least 10 per cent and profit growth in FY26 and in the latest quarter, and net profit rose in FY26 and in the latest quarter.

This list covers companies with Kotak Mutual Fund or one of its schemes listed among its top domestic institutional holders, a return on equity of at least 10 per cent and profit growth in FY26 and in the latest quarter, rising profit in FY26 and the latest quarter, market capitalisation above Rs 1,00,000 crore, and complete, verifiable financials, ranked by market capitalisation. Each company has a market cap above Rs 1 lakh crore. Investors screening Kotak mutual fund stocks usually begin with size and balance sheet strength, and this list follows the same logic. All figures are as of 28 October 2026 and are drawn from NSE and BSE data and company filings.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • What Are Kotak Mutual Fund Stocks and Why Do They Attract Multibagger Interest?
  • Kotak Mutual Fund Stocks at a Glance: Price, Market Cap, PE, ROE and Price to Book
  • Shriram Finance: 38.64% Profit CAGR Since FY22
  • Torrent Pharma: 28.79% Profit CAGR Since FY22
  • BSE: 78.30% Profit CAGR Since FY22
  • Indian Bank: 32.28% Profit CAGR Since FY22
  • Kotak Mutual Fund Stocks: Financial Comparison on Growth and Margins
  • Institutional Holding in Shriram Finance, Torrent Pharma, BSE and Indian Bank
  • Risks to Weigh in Kotak Mutual Fund Stocks
  • How to Choose Between Kotak Mutual Fund Stocks
  • Conclusion
  • Frequently Asked Questions on Kotak Mutual Fund Stocks to Watch
    • Which are the best Kotak mutual fund stocks to watch for multibagger potential?
    • Is BSE a good stock for long-term investors?
    • Can Shriram Finance become a multibagger from here?
    • What is the market cap of Shriram Finance, Torrent Pharma, BSE and Indian Bank?
    • What are the risks of investing in Kotak mutual fund stocks?
    • Why is Torrent Pharma trading at a PE of 80.23?
    • How much do institutions hold in Shriram Finance, Torrent Pharma, BSE and Indian Bank?

What Are Kotak Mutual Fund Stocks and Why Do They Attract Multibagger Interest?

Kotak mutual fund stocks are shares of large companies in which Kotak Mutual Fund or one of its schemes is named among the top domestic institutional holders in the latest shareholding pattern. The four here cover lending, pharmaceuticals, a stock exchange and public sector banking.

When a leading fund house like Kotak Mutual Fund holds a large stake, it shows that its research teams have studied the business closely and backed it with investors money. For Kotak mutual fund stocks, both FY26 and the latest quarter showed growth. For Kotak mutual fund stocks, checking each result against the latest quarter matters more than any single ratio. The next sections explain what stands out in each of Kotak mutual fund stocks, using FY26 and latest quarter data. Prices move daily, so recheck the figures for Kotak mutual fund stocks before you decide.

Kotak Mutual Fund Stocks at a Glance: Price, Market Cap, PE, ROE and Price to Book

Prices are closing prices as of 28 October 2026. Indian Bank has the lowest PE of the group at 8.36, while BSE posts the highest return on equity at 37.42%.

Stock CMP (Rs) Market Cap (Rs Cr) PE Industry PE ROE Price to Book 52-Week Range (Rs)
Shriram Finance 826.05 2,04,755 18.09 17.68 15.21% 1.94 662.25 to 1,153.70
Torrent Pharmaceuticals 4,557 1,72,983 80.23 36.42 25.49% 20.57 3,480.60 to 5,250.00
BSE Ltd 3,485 1,49,244 52.89 42.42 37.42% 22.36 2,326.10 to 4,446.80
Indian Bank 839.80 1,10,586 8.36 12.02 16.02% 1.38 756.50 to 1,000.90

Shriram Finance: 38.64% Profit CAGR Since FY22

Shriram Finance is a major NBFC focused on commercial vehicle, small business and personal loans. It reported FY26 total income of Rs 48,192.65 crore, up 15.13% year on year, and net profit of Rs 10,004.20 crore, up 6.16%. Net profit has compounded at 38.64% a year since FY22, while total income has grown 25.75% a year.

In the June 2026 quarter, total income rose 16.26% to Rs 13,418.74 crore and net profit grew 59.95% to Rs 3,447.26 crore. The share price has gained 239.61% over five years and 40.91% over the past year. Domestic institutions raised their holding from 18.66% in September 2025 to 19.90% in June 2026. The stock trades at a PE of 18.09 against an industry PE of 17.68, with a return on equity of 15.21%.

Torrent Pharma: 28.79% Profit CAGR Since FY22

Torrent Pharmaceuticals makes branded medicines for chronic therapies such as cardiac, gastro-intestinal and central nervous system care in India and overseas. It reported FY26 revenue of Rs 13,886.15 crore, up 20.34% year on year, and net profit of Rs 2,138.18 crore, up 11.87%. Net profit has compounded at 28.79% a year since FY22, while revenue has grown 12.38% a year. Operating margin was 22.70% in FY26.

The stock trades at a PE of 80.23 against an industry PE of 36.42, with a return on equity of 25.49%. In the June 2026 quarter, revenue rose 56.29% to Rs 4,909 crore and net profit grew 3.28% to Rs 566 crore. The share price has gained 194.63% over five years and 29.72% over the past year. Domestic institutions raised their holding from 9.28% in September 2025 to 12.87% in July 2026.

BSE: 78.30% Profit CAGR Since FY22

BSE Ltd operates one of India’s two major stock exchanges and earns from trading, listing, data and clearing services. It reported FY26 revenue of Rs 5,148.10 crore, up 59.07% year on year, and net profit of Rs 2,475.30 crore, up 87.94%. Net profit has compounded at 78.30% a year since FY22, while revenue has grown 56.26% a year. Operating margin was 68.39% in FY26. The debt-to-equity ratio is 0.00, which keeps interest costs low.

In the June 2026 quarter, revenue rose 63.41% to Rs 1,706.72 crore and net profit grew 62.15% to Rs 872.66 crore. The share price has gained 2101.66% over five years and 37.49% over the past year. Domestic institutions raised their holding from 13.51% in June 2025 to 24.15% in June 2026. The stock trades at a PE of 52.89 against an industry PE of 42.42, with a return on equity of 37.42%.

Indian Bank: 32.28% Profit CAGR Since FY22

Indian Bank is a government-owned bank with a strong presence in South India and a growing national network. It reported FY26 total income of Rs 78,332.70 crore, up 8.72% year on year, and net profit of Rs 12,226.99 crore, up 11.21%. Net profit has compounded at 32.28% a year since FY22, while total income has grown 14.07% a year.

The stock trades at a PE of 8.36 against an industry PE of 12.02, below the sector average, with a return on equity of 16.02%. The dividend yield is 2.22%. In the September 2026 quarter, total income rose 21.09% to Rs 23,335.98 crore and net profit grew 13.36% to Rs 3,446.86 crore. The share price has gained 396.82% over five years and 10.47% over the past year. Foreign investors raised their holding from 4.68% in September 2025 to 6.86% in September 2026.

Kotak Mutual Fund Stocks: Financial Comparison on Growth and Margins

The table compares scale and growth across these Kotak mutual fund stocks. Latest quarter means the most recent reported quarter for each company, and only metrics that are positive for every company are shown.

Stock Total Income (Rs Cr) Net Profit (Rs Cr) Income Growth (YoY) 4-Year Income CAGR 4-Year Net Profit CAGR
Shriram Finance 48,192.65 10,004.20 15.13% 25.75% 38.64%
Torrent Pharma 13,886.15 2,138.18 20.34% 12.38% 28.79%
BSE 5,148.10 2,475.30 59.07% 56.26% 78.30%
Indian Bank 78,332.70 12,226.99 8.72% 14.07% 32.28%

Check the Univest Screener for live data on these Kotak mutual fund stocks

Institutional Holding in Shriram Finance, Torrent Pharma, BSE and Indian Bank

Institutional holding shows who is backing these Kotak mutual fund stocks alongside the promoter. The table uses the latest reported quarter for each. Shriram Finance has the deepest institutional backing, with FII and DII together holding 74.67% as of June 2026. Domestic institutions increased their holding over the past year in Shriram Finance (from 18.66% to 19.90%), Torrent Pharma (from 9.28% to 12.87%) and BSE (from 13.51% to 24.15%).

Stock Promoter FII DII Public Quarter
Shriram Finance 20.30% 54.77% 19.90% 5.04% June 2026
Torrent Pharma 60.78% 17.97% 12.87% 8.38% July 2026
BSE Nil 21.32% 24.15% 54.53% June 2026
Indian Bank 73.84% 6.86% 16.77% 2.53% September 2026

Risks to Weigh in Kotak Mutual Fund Stocks

Being careful with Kotak mutual fund stocks means looking at what can slow the story as well as what can speed it up. Four points matter most:

  • Past growth may not repeat.
  • Share prices can move sharply in either direction.
  • Valuation: Torrent Pharma trades at a PE of 80.23 against an industry PE of 36.42, so earnings need to keep growing to support the price.
  • Concentration: Holding all 4 names puts the allocation in one sector, so size each position to match your risk appetite.

How to Choose Between Kotak Mutual Fund Stocks

Picking from Kotak mutual fund stocks comes down to four checks, applied in order.

  1. Check asset quality and net interest margin first, then return on equity and price to book. Debt-to-equity does not apply to lenders.
  2. Compare each PE with the industry PE (12.02 to 42.42) and ask whether the growth rate justifies any gap.
  3. Track net profit growth, the operating margin and the return on equity in every quarterly result.
  4. Stagger entries across quarters and review institutional holding every reporting season.

Download the Univest iOS App or Univest Android App to track Shriram Finance, Torrent Pharma, BSE and Indian Bank live prices.

Conclusion

Among Kotak mutual fund stocks, Shriram Finance stands out for the largest market cap at Rs 2,04,755 crore, Torrent Pharma for 20.34% revenue growth in FY26, BSE for the highest return on equity at 37.42% and Indian Bank for the lowest PE of the group at 8.36. Which one suits a portfolio depends on how much valuation risk it can carry, so staggering entries and reviewing each quarterly result is a sound habit. Investors comparing Kotak mutual fund stocks should rank them on growth, financial strength and the price paid, and anyone who wants personalised guidance can consult a SEBI-registered advisor before acting.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Frequently Asked Questions on Kotak Mutual Fund Stocks to Watch

Which are the best Kotak mutual fund stocks to watch for multibagger potential?

Ans. Shriram Finance, Torrent Pharma, BSE and Indian Bank are the 4 names this list highlights, with market caps of Rs 2,04,755 crore, Rs 1,72,983 crore, Rs 1,49,244 crore and Rs 1,10,586 crore respectively. Shriram Finance is notable for the largest market cap at Rs 2,04,755 crore. Torrent Pharma stands out for 20.34% revenue growth in FY26. BSE offers the highest return on equity at 37.42%. Indian Bank brings the lowest PE of the group at 8.36. These are watchlist names for Kotak mutual fund stocks, not recommendations, so match each one to your own risk profile and time horizon.

Is BSE a good stock for long-term investors?

Ans. BSE has a return on equity of 37.42%, a PE of 52.89 against an industry PE of 42.42 and a market cap of Rs 1,49,244 crore. Net profit has compounded at 78.30% a year since FY22, and FY26 revenue rose 59.07% while June 2026 quarter net profit grew 62.15%. Long-term returns in Kotak mutual fund stocks depend on earnings growth and the price paid at entry, so staggering purchases and consulting a SEBI-registered advisor is sensible.

Can Shriram Finance become a multibagger from here?

Ans. Shriram Finance has already gained 239.61% in five years, so another multi-fold move would need sustained earnings growth. A multibagger outcome in Kotak mutual fund stocks requires earnings to keep growing faster than the market for several years. Net profit has compounded at 38.64% a year since FY22, and FY26 revenue rose 15.13%. At a PE of 18.09 against an industry PE of 17.68, valuation should be checked against that growth before investing.

What is the market cap of Shriram Finance, Torrent Pharma, BSE and Indian Bank?

Ans. As of 28 October 2026, Shriram Finance has a market cap of Rs 2,04,755 crore, Torrent Pharma has a market cap of Rs 1,72,983 crore, BSE has a market cap of Rs 1,49,244 crore and Indian Bank has a market cap of Rs 1,10,586 crore. All of them qualify as largecaps. Market cap changes daily with the share price, so check the latest figure on the Univest Screener or on NSE before taking a decision on Kotak mutual fund stocks.

What are the risks of investing in Kotak mutual fund stocks?

Ans. The main risks are market swings, slower growth than expected and valuations that already reflect good news. Companies with strong balance sheets and steady earnings handle these better. Torrent Pharma trades at a PE of 80.23 against an industry PE of 36.42, so earnings growth needs to hold up.

Why is Torrent Pharma trading at a PE of 80.23?

Ans. Torrent Pharma’s PE of 80.23 compares with an industry PE of 36.42. The market is paying a premium for a return on equity of 25.49%, profit growth of 28.79% a year since FY22 and FY26 revenue growth of 20.34%, which also means the stock is more sensitive if growth slows. Investors in Kotak mutual fund stocks who are comfortable with higher valuation risk may prefer to stagger purchases instead of investing in one go.

How much do institutions hold in Shriram Finance, Torrent Pharma, BSE and Indian Bank?

Ans. As of the latest reported quarter, FII and DII together hold 74.67% of Shriram Finance (54.77% and 19.90%), 30.84% of Torrent Pharma (17.97% and 12.87%), 45.47% of BSE (21.32% and 24.15%) and 23.63% of Indian Bank (6.86% and 16.77%). Rising institutional holding is a useful signal in Kotak mutual fund stocks, though it should be read with earnings trends rather than on its own.



Kotak mutual fund sector Kotak mutual fund stocks
Author: Manan Bisht
Manan Bisht is a Financial Content Writer at Univest, covering Indian equity markets with a focus on investor education, stock analysis, and personal finance. With over a year of hands-on experience in financial content creation, he translates complex market concepts into clear, beginner-friendly articles for retail investors. He holds a Bachelor of Commerce (B.Com) from Delhi University, giving him a strong academic grounding in financial accounting, economics, business law, and capital markets. This foundation shapes how he approaches every article — grounding analysis in verified financial fundamentals rather than speculation. He is also a SEBI Investor Certification holder, reinforcing his understanding of securities markets, investor rights, and SEBI regulatory frameworks — directly relevant to the YMYL (Your Money, Your Life) content he publishes. All articles are reviewed by Univest's in-house equity research team, led by Ankit Jaiswal, Senior Research Analyst, to meet SEBI editorial standards.

Leave a Reply Cancel reply